Key result
Comprehensive cytomolecular testing successfully identifies rare ROS1-rearranged lung adenocarcinoma presenting with effusions.
Why the study?
ROS1-rearranged lung adenocarcinoma occurring in very young men with a fluid-dominant presentation is unusual and may lead to diagnostic pitfalls.
Case Report (n=1)
This case highlights the diagnostic pitfalls of pericardial fluid cytology in young patients and emphasizes the importance of cell blocks and molecular testing to identify rare malignancies like ROS1-rearranged lung adenocarcinoma.
Raises awareness for ROS1 testing in young never-smokers with multi-compartment effusions; leaves open optimal diagnostic thresholds in fluid-dominant presentations.
ROS1 ‐rearranged lung adenocarcinoma is a rare subset of non‐small‐cell lung cancer, typically occurring in young never‐smokers. Its occurrence in very young men with a fluid‐dominant presentation is unusual and may lead to diagnostic pitfalls. We herein report a case of ROS1 ‐rearranged lung adenocarcinoma in a never‐smoking man in his early 20s who presented with pericardial, pleural, and peritoneal effusion. The initial cytological assessment of the pericardial fluid, interpreted in the context of the patient's very young age, favored reactive mesothelial proliferation. Clusters with nuclear eccentricity and prominent nucleoli prompted the preparation of a cell block. Hematoxylin and eosin staining revealed cohesive nests, cords of tumor cells, and true gland‐forming tubular structures with scattered mucin‐containing cells. Immunohistochemistry confirmed primary lung adenocarcinoma, and a molecular analysis identified a ROS1 rearrangement. This case underscores the rarity of ROS1 ‐rearranged adenocarcinoma in a very young never‐smoking man, its atypical fluid‐dominant manifestation, particularly pericardial effusion, and the importance of a systematic diagnostic approach that incorporates smear cytology, cell block, immunohistochemistry, and molecular testing, supported by multidisciplinary discussion to avoid a misdiagnosis and guide targeted therapy.
No takes yet. Share an insight, caveat, or question.
Kawakami et al. (2025) conducted a case report in ROS1-rearranged lung adenocarcinoma (n=1). Systematic diagnostic approach (smear cytology, cell block, immunohistochemistry, molecular testing) was evaluated on Diagnosis of ROS1-rearranged lung adenocarcinoma. A systematic diagnostic approach incorporating smear cytology, cell block, immunohistochemistry, and molecular testing successfully identified ROS1-rearranged lung adenocarcinoma in a young man.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: